0.5877

2.38% -0.0143

Citius Pharmaceuticals Inc (CTXR)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt CTXR? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$0.602

Offen:

$0.602

24-Stunden-Volumen:

299.62K

Relative Volume:

0.55

Marktkapitalisierung:

$16.13M

Einnahmen:

$5.61M

Nettoeinkommen (Verlust:

$-55.45M

KGV:

-0.2287

EPS:

-2.5703

Netto-Cashflow:

$-42.35M

1W Leistung:

-2.39%

1M Leistung:

-5.59%

6M Leistung:

-28.01%

1J Leistung:

-48.90%

1-Tages-Spanne:

$0.58

$0.6099

1-Wochen-Bereich:

$0.563

$0.6143

52-Wochen-Spanne:

$0.4687

$2.19

Citius Pharmaceuticals Inc Stock (CTXR) Company Profile

Firmenname

Citius Pharmaceuticals Inc

Sektor

Healthcare (1074)

Branche

Biotechnology (600)

Telefon

(908) 967-6676

Adresse

11 COMMERCE DRIVE, CRANFORD, NJ

Mitarbeiter

Twitter

Nächster Verdiensttermin

2026-08-18

Neueste SEC-Einreichungen

CTXR's Discussions on Twitter

Compare CTXR vs VRTX, REGN, ARGX, MRNA, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CTXR Citius Pharmaceuticals Inc	0.5877	16.47M	5.61M	-55.45M	-42.35M	-2.5703
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-12-30	Hochstufung	D. Boral Capital	Hold → Buy
2021-11-30	Eingeleitet	Maxim Group	Buy

Citius Pharmaceuticals Inc Aktie (CTXR) Neueste Nachrichten

Aug 21, 2026

Citius Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView

Aug 21, 2026

Nasdaq gives Citius (NASDAQ: CTXR) more time before $1 delisting risk - Stock Titan

Aug 21, 2026

Aug 19, 2026

H.C. Wainwright reiterates Citius Pharmaceuticals stock rating at buy By Investing.com - Investing.com South Africa

Aug 19, 2026

Aug 18, 2026

Citius (CTXR) Market-Day Review: Finishes 1.78% Higher at $0.57 in the Latest Session; Key Levels: the Near-Term Reference Band Stretches From $0.54 to $0.60 in the Available RecordWMA Signal - vinanet.vn

Aug 18, 2026

Aug 16, 2026

Citius Pharmaceuticals (NASDAQ:CTXR): What Does Today’s Clinical Focus Checkpoint Mean? - Kalkine Media

Aug 16, 2026

Citius Pharmaceuticals (NASDAQ:CTXR): What Does Today’s Program Priorities Checkpoint Mean? - Kalkine Media

Aug 16, 2026

Is Citius Pharmaceuticals (CTXR) Worth the Investment After Q3 E - GuruFocus

Aug 16, 2026

CTXR Q4 2025 Earnings: EPS Misses Estimates by 45.04% While Stock Gains 3.0%Analyst Earnings Estimate - vinanet.vn

Aug 16, 2026

Citius Pharmaceuticals (CTXR) Gains 3% to $0.76 as Buyers Defend SupportBull Pennant - dars.gov.et

Aug 16, 2026

Citius Pharmaceuticals Reports LYMPHIR Revenue Growth, Explores CAR-T Combination - The Clinical Trial Vanguard

Aug 16, 2026

Aug 14, 2026

Citius Pharma Reports First LYMPHIR Revenue of $7.1M in Nine Months - Minichart

Aug 14, 2026

Citius Oncology (CTOR) director Jonathan Peri files Form 3 showing no common shares - Stock Titan

Aug 14, 2026

Citius Pharma Q3 EPS beats estimate, sales miss by 72% - scanx.trade

Aug 14, 2026

Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - The AI Journal

Aug 14, 2026

Citius Pharmaceuticals Reports Q3 2026 Financial Results and LYMPHIR Progress - Intellectia AI

Aug 14, 2026

CTXR: LYMPHIR's launch drove $7.1M revenue and 77% gross margin, offset by higher launch costs - TradingView

Aug 14, 2026

Citius Oncology (CTOR) grows LYMPHIR sales but posts $41M nine-month loss - Stock Titan

Aug 14, 2026

Citius Oncology, Inc. Announces Appointment of Jonathan Peri, Ph.D., J.D., as Independent Director, Effective August 10, 2026 - marketscreener.com

Aug 14, 2026

Citius Pharmaceuticals (CTXR) holders report 3.0M-share, 9.9% beneficial stake - Stock Titan

Aug 14, 2026

CTXR Q3'26 Earnings: EPS estimate is (0.36) USD - TradingView

Aug 14, 2026

Aug 13, 2026

Citius Oncology appoints independent director Peri to board of directors - ROI-NJ

Aug 13, 2026

Aug 12, 2026

People on the Move: Jonathan Peri, Ph.D., J.D., Joins Citius Oncology’s Board of Directors - BioBuzz

Aug 12, 2026

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri - Morningstar

Aug 12, 2026

Citius Pharmaceuticals expands Citius Oncology board to nine with appointment of Jonathan Peri - Traders Union

Aug 12, 2026

Citius Oncology Adds Jonathan Peri to Board as LYMPHIR Commercialization Advances - citybiz

Aug 12, 2026

Citius Oncology appoints Jonathan Peri to board of directors - Investing.com

Aug 12, 2026

Aug 11, 2026

Citius Pharmaceuticals (CTXR) Edges Higher by 1.92%, Maintaining Position Above Key Support at $0.69TWAP Entry - vinanet.vn

Aug 11, 2026

Aug 09, 2026

BREAKING: THE PRINTING HAS STARTED! Robert De Niro (xWXxQcdGpe) - Mshale

Aug 09, 2026

Aug 08, 2026

CTXR Q4 2025 Earnings: EPS Misses Estimates by 45.04% as Shares Rise 6.23%Banking Earnings Report - vinanet.vn

Aug 08, 2026

Aug 07, 2026